Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Clinical trial NCT01520870 · COMPLETED
Trial details
- NCT number
- NCT01520870
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-01
- Primary completion
- 2015-04-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.